Key MessageIdentification of a subset of CRC patients with *HER2* abnormalities represents an opportunity for precision oncology. Trastuzumab combined with lapatinib/pertuzumab inhibited growth of *HER2*-amplified CRC cells/xenografts, paving the way for clinical translation. The clinical benefit of anti-HER2 therapy has been shown in *HER2*-amplified CRC patients, most of whom are resistant to anti-EGFR therapy.

Introduction
============

Few clinically actionable genetic abnormalities have been identified in primary tumors, metastases, or blood of patients with colorectal cancer (CRC) \[[@mdy100-B1]\]. While the role of human epidermal growth factor receptor 2 (*HER*2) as a biomarker for prognosis in CRC remains uncertain, its role as a therapeutic target is rising \[[@mdy100-B4]\]. HER2 is also emerging as a negative predictor of response to epidermal growth factor receptor (EGFR)-targeted treatments \[[@mdy100-B9]\]. Hence, patients with HER2-positive CRC might have fewer treatment options and carry an inferior prognosis. In this review, we consider the role of HER2 in CRC as an oncogenic driver and prognostic and predictive biomarker, present HER2 testing methods utilized specifically in patients with CRC, and discuss clinical diagnostic and therapeutic data supporting HER2 as a novel therapeutic target in CRC.

HER2 as an oncogenic driver in CRC
==================================

HER2 is the only member of the EGFR family that does not bind ligands; it is activated via heterodimerization with other ligand-bound receptors \[[@mdy100-B10]\], with the strongest mitogenic signals created by HER2--HER3 heterodimers. HER2 overexpression, usually caused by gene amplification, allows HER2 activation even in the absence of ligand bound to the other partners \[[@mdy100-B11]\]. Overexpression or amplification of HER2 has been reported in 13%--20% of breast cancers \[[@mdy100-B12]\], 7%--34% of gastric cancers \[[@mdy100-B13]\], and 1.9%--14.3% of lung carcinomas \[[@mdy100-B14]\]. Diverse rates of HER2 overexpression have been reported in CRC (Table [1](#mdy100-T1){ref-type="table"} \[[@mdy100-B9], [@mdy100-B15]\]), with rates of membranous expression ranging from 2% to 11% \[[@mdy100-B16]\]. A number of factors may account for these differing rates, including small study populations, different antibodies for immunohistochemistry (IHC), analysis of distinct subgroups of patients with heterogeneous clinico-pathologic CRC characteristics, and application of diverse scoring systems \[[@mdy100-B18]\]. More recent studies consistently indicate that HER2 overexpression accounts for approximately 2% of all CRCs \[[@mdy100-B9], [@mdy100-B16], [@mdy100-B18]\], increasing up to 5% in stage III \[[@mdy100-B9]\] or IV *KRAS* exon 2 wild-type tumors \[[@mdy100-B6], [@mdy100-B16], [@mdy100-B17]\]. Table 1.Incidence of HER2 overexpression and association with prognosis in CRCHER2 testing by IHC/ISHReferencesPatients, *N*StageMonoclonal antibodyHER2 3+, %LocationPrognostic roleNi et al. \[[@mdy100-B15]\]4913----1.4ColorectalYesLaurent-Puig et al. \[[@mdy100-B9]\]1795III4B5 Ventana1.4 (*n*=21/1457)ColonYes for IHC/FISH only for RFS but not OS[^a^](#tblfn1){ref-type="table-fn"}Richman et al. \[[@mdy100-B16]\]1914II--IIIA 0485 Dako1.3ColorectalNo1342IVA 0485 Dako2.2NoValtorta et al. \[[@mdy100-B17]\]1086--4B5 Ventana/ Hercep-Test4.1ColorectalNot assessedIngold Heppner et al. \[[@mdy100-B18]\]1645I-IVClone SP30.5 (1.6 total CISH+)ColorectalTrend toward worse survivalSong et al. \[[@mdy100-B19]\]106pT1, pT2, pT34B57.5 (2/3+)ColorectalNoSP33.8 (2/3+)NoConradi et al. \[[@mdy100-B20]\]264II/III rectalPATHWAY (Ventana)5.9 (*n*=10/169 pretreatment biopsies)RectalYesKruwszewski et al. \[[@mdy100-B21]\]202II--IVA 048515.3ColorectalNoKountourakis et al. \[[@mdy100-B22]\]106--NCL-CB112.8 membranousColorectalNoSchuell et al. \[[@mdy100-B23]\]77I--IVHercep-Test3ColorectalTrend toward worse survivalEssapen et al. \[[@mdy100-B24]\]170II--IIIHM64.1354.1 (2+, cytoplasmic)ColorectalYes (cytoplasmic, stage III)40.0 (2+, membranous)McKay et al. \[[@mdy100-B25]\]249I--IVNCL-CB113.2ColorectalNoRossi et al. \[[@mdy100-B26]\]156I--III--4 (2/3+)ColorectalNoOsako et al. \[[@mdy100-B27]\]146--Nichirei4.5 (*HER2* amplification)ColorectalYesKapitanović et al. \[[@mdy100-B28]\]221--Ab-343 (*n*=67/155 adenocarcinomas)ColorectalYes**Molecular profiling of HER2ReferencesPatients, *N*StageMethod*HER2* amplification, %LocationPrognostic role**Ross et al. \[[@mdy100-B29]\]8874--CGS4.9 (and/or short variant alterations)ColorectalNot assessedShimada et al. \[[@mdy100-B30]\]201I--IVCGS5.0ColorectalNot assessedGong et al. \[[@mdy100-B31]\]138--NGS5.1ColorectalNot assessedSchrock et al. \[[@mdy100-B32]\]143--ctDNA4 (≥1 *HER2* activating mutation or amplification)ColorectalNot assessedLaurent-Puig et al. \[[@mdy100-B9]\]1795IIINGS2.9 (5.6 alterations *KRAS* wild type)ColorectalFor RFS and OS on anti-EGFR-based first-line therapyTakegawa et al. \[[@mdy100-B33]\]18--ctDNA22 (HER2 gene copy number ratio 1.25)ColorectalNot assessedEdenfield et al. \[[@mdy100-B34]\]4110--NGS, IHC/ISH1.8ColorectalNot assessed**HER2 by primary tumor locationReferencesPatients, *N*StageMethod*HER2* amplification, % by locationPrognostic role**Weinberg et al. \[[@mdy100-B35]\]1602--CISH5.7 left colon (patients ≤45 years)Not assessed2.1 left colon (patients ≥65 years)Marshall et al. \[[@mdy100-B36]\]496--CISH5.4 rectumNot assessed3.4 descending colon1.3 right colonSiena et al. \[[@mdy100-B37]\]33 (all HER2+)IVIHC/FISH64 distal colonNot assessed21 rectal15 proximal colonRaghav et al. \[[@mdy100-B38]\]97--NGS, IHC/ISH9.3 distalFor PFS on anti-EGFR-based therapy in 2nd/3rd line; not for OS5.2 proximalIngold Heppner et al. \[[@mdy100-B18]\]1645I--IVIHC2.1 sigmoid colon--rectumTrend toward worse survival0.9 cecum--descending colon[^3][^4]

HER2 testing in CRC
===================

Although routinely used in breast and gastric cancer, IHC and fluorescent in situ hybridization (ISH; FISH) or silver-enhanced ISH (SISH) techniques have not been modified for assessment of HER2 overexpression/amplification in CRC. Table [2](#mdy100-T2){ref-type="table"} \[[@mdy100-B13], [@mdy100-B17], [@mdy100-B39], [@mdy100-B40]\] and [supplementary Figure S1](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online, summarize current IHC/ISH testing guidelines in breast, gastric, and CRC. Table 2.Guidelines for HER2 testing in breast, gastric, and CRCNegativeEquivocalPositive**Breast cancer** (Wolff et al. \[[@mdy100-B39]\])**[IHC]{.ul}**[score 0:]{.ul} absence of staining or ≤10% weak incomplete membrane staining**[IHC]{.ul}**[score 1]{.ul}+: incomplete faint/barely perceptible membrane staining \>10%**ISH** \<4 copies or *HER2*: CEP17 \<2 in \>10% of cells**[IHC]{.ul}**[score 2]{.ul}+: \>10% moderate complete or strong or moderate incomplete membrane staining, ≤10% strong complete membrane staining**ISH mandatoryISH***HER2* 4--6 copies or *HER2*: CEP17 \<2 with ≥4 and \<6 copies in \>10% of cells**[IHC]{.ul}**[score 3]{.ul}+: \>10% strong complete membrane staining**ISH not mandatoryISH** ≥6 copies or *HER2*: CEP17 ≥2 in \>10% of cells**Gastric cancer surgical specimen** (Rüschoff et al. \[[@mdy100-B13]\])**[IHC]{.ul}**[score 0:]{.ul} no reactivity or membranous reactivity in \<10% of tumor cells**[IHC]{.ul}**[score 1]{.ul}+: faint/barely perceptible membranous reactivity in ≥10% of cells; cells reactive only in part of their membrane**ISH** \<4 copies or *HER2*: CEP17 \<1.8**[IHC]{.ul}**[score 2]{.ul}+: weak to moderate complete, basolateral, or lateral membranous reactivity in ≥10% of tumor cells **ISH mandatoryISH***HER2* 4--6 copies or *HER2*: CEP17 1.8--2 in ≥10% of cells**[IHC]{.ul}**[score 3]{.ul}+: strong complete, basolateral, or lateral membranous reactivity in ≥10% of tumor cells**ISH not mandatoryISH** \>6 copies or *HER2*: CEP17 \>2 in ≥10% of cells**Gastric cancer biopsy** (Bartley et al. \[[@mdy100-B40]\])**[IHC]{.ul}**[score 0:]{.ul} no reactivity or no membranous reactivity in any tumor cell**[IHC]{.ul}**[score 1]{.ul}+: tumor cell cluster[^a^](#tblfn3){ref-type="table-fn"} with a faint/barely perceptible membranous reactivity irrespective of percentage of tumor cells stained**ISH** \<4 copies or *HER2*: CEP17 \<2**[IHC]{.ul}**[score 2]{.ul}+: tumor cell cluster[^a^](#tblfn3){ref-type="table-fn"} with a weak to moderate complete, basolateral, or lateral membranous reactivity irrespective of percentage of tumor cells stained**ISH mandatoryISH***HER2* 4--6 copies or *HER2*: CEP17 1.8--2.0 in ≥10% of cells indicates another 20 cells should be scored in a different target area[^b^](#tblfn4){ref-type="table-fn"}**[IHC]{.ul}**[score 3]{.ul}+: tumor cell cluster[^a^](#tblfn3){ref-type="table-fn"} with a strong complete, basolateral, or lateral membranous reactivity irrespective of percentage of tumor cells stained**ISH not mandatoryISH***HER2* \>6 copies or *HER2*: CEP17 ≥2 in ≥10% of cells**Colorectal cancer VENTANA** (based on Rüschoff et al. \[[@mdy100-B13]\])**[IHC]{.ul}**[score 0:]{.ul} no staining or staining in \<10% of cells**[IHC]{.ul}**[score 1]{.ul}+: faint, barely perceptible in \>10% of the cells; segmental or granular**ISH** \<4 copies or *HER2*: CEP17 \<1.8**[IHC]{.ul}**[score 2]{.ul}+: weak to moderate staining in \>10% of cells; circumferential, basolateral, or lateral**ISH mandatoryISH***HER2* 4--6 copies or *HER2*: CEP17 1.8--2 in ≥10% of cells**[IHC]{.ul}**[score 3]{.ul}+: intense in \>10% of cells; circumferential, basolateral, or lateral**ISH mandatoryISH***HER2* \>6 copies or *HER2*: CEP17 \>2 in ≥10% of cells**Colorectal cancer HERACLES** (Valtorta et al. \[[@mdy100-B17]\])**[IHC]{.ul}**[score 0:]{.ul} no staining**[IHC]{.ul}**[score 1]{.ul}+: faint staining (segmental or granular); moderate staining \<50% of cells (any cellularity); intense staining ≤10% cells[^c^](#tblfn5){ref-type="table-fn"}**[IHC]{.ul}**[score 2]{.ul}+: moderate staining in ≥50% of cells[^c^](#tblfn5){ref-type="table-fn"}**ISH mandatory if \>50% cellularity confirmed following IHC retestISH***HER2*: CEP17 ≥2 in ≥50% of cells**[IHC]{.ul}**[score 3]{.ul}+: intense staining in ≥50% of cells[^c^](#tblfn5){ref-type="table-fn"}**ISH not mandatory**; intense staining in \>10% but \<50**%** of cells[^c^](#tblfn5){ref-type="table-fn"}**ISH mandatory if \>10% cellularity confirmed following IHC retestISH***HER2*: CEP17 ≥2 in ≥50% of cells[^5][^6][^7][^8]

Valtorta and colleagues conducted a diagnostic study to define specific IHC/ISH criteria to determine *HER2* positivity in CRC, and to accurately select patients with HER2-positive, *KRAS* wild-type metastatic CRC (mCRC) for enrollment in the phase II HERACLES (**HER**2 **A**mplification for **C**olorecta**L** Cancer **E**nhanced **S**tratification) trial of HER2-targeted therapy \[[@mdy100-B17]\].

HER2 protein expression was assessed manually by IHC using the HercepTest antibody (Dako A/S Glostrup, Glostrup, Denmark), and automatically using the VENTANA 4B5 antibody on the BenchMark ULTRA platform (Ventana Medical Systems, Inc. Tucson, AZ, USA). *HER2* amplification was evaluated by FISH using a PathVysion HER2 DNA Probe Kit (Abbott Laboratories, Abbott Park, IL), and by SISH with a VENTANA 4B5 Inform HER2 dual-color assay on the BenchMark ULTRA platform \[[@mdy100-B17]\]. All samples were centrally scored. HER2 positivity was defined as tumors with HER2 3+ score in ≥50% of cells by IHC, or HER2 2+ score and *HER2*: CEP17 ratio ≥2 in ≥50% of cells by FISH \[[@mdy100-B17]\]. Referred to as the HERACLES Diagnostic Criteria, these are more stringent than those adopted for defining HER2 positivity in breast and gastric tumors.

In an archival cohort of 256 patients tested by an international panel of HER2 expert pathologists, and a clinical validation cohort of 1277 patients, 5% of patients with *KRAS* wild-type mCRC had HER2-positive tumors according to HERACLES Diagnostic Criteria \[[@mdy100-B17], [@mdy100-B37]\]. In recent CRC studies, applying scoring consistent with these criteria, the rate of HER2 positivity (IHC 2+/3+, or *HER2* ISH amplification) ranged from 1.6% to 6.3% \[[@mdy100-B18], [@mdy100-B41]\], in contrast to the wide-ranging values previously reported (Table [1](#mdy100-T1){ref-type="table"} \[[@mdy100-B9], [@mdy100-B15]\]).

*HER2* amplification in CRC has also been explored using molecular techniques such as next-generation sequencing (NGS) and comprehensive genomic sequencing (CGS), with rates ranging from 1.8% to 22.0% (Table [1](#mdy100-T1){ref-type="table"} \[[@mdy100-B9], [@mdy100-B29]\]). Molecular profiling using NGS, IHC, and chromogenic ISH (CISH)/FISH in a large dataset of patients with HER2-overexpressing CRC revealed a 1.8% (81/4110 patients) incidence of *HER2* overexpression, with 97% concordance between HER2 protein expression and gene amplification \[[@mdy100-B34]\]. Shimada and colleagues retrospectively assessed the HER2 status of 201 patients with stages I--IV CRC using IHC and FISH compared with using CGS \[[@mdy100-B30]\]. Ten patients (5%) whose tumors were diagnosed as HER2 positive by HERACLES Diagnostic Criteria also had *HER2* amplifications according to CGS. HER2 status and *HER2* amplifications at the primary site were identical in all patients analyzed (*P *\<* *0.001), indicating the utility of CGS for detecting HER2-positive CRC.

The use of liquid biopsies to determine *HER2* status was first explored using blood samples from patients with breast cancer \[[@mdy100-B42], [@mdy100-B43]\] and was recently applied in patients with mCRC \[[@mdy100-B32], [@mdy100-B33]\]. Takegawa and colleagues analyzed circulating tumor DNA (ctDNA) from 18 patients with cetuximab-resistant mCRC, of which four (22%) were classified as *HER2* positive \[[@mdy100-B33]\]. Concordance of *HER2* amplification between plasma ctDNA and tissue samples was demonstrated by rebiopsy of the metastatic lesion of one of these four patients. In a separate analysis, Schrock and coworkers isolated ctDNA from 143 patients with CRC and identified five patients (4%) with *HER2* activating mutations or amplification \[[@mdy100-B32]\].

IHC is readily available and successful trials of therapeutic HER2 blockade have been based on IHC results. However, it is likely that in the near future, molecular screening using NGS may replace IHC. Although NGS is now more expensive, it has the advantage of capturing a wider range of genome abnormalities including HER2-activating mutations (see section 'Are HER2 mutations actionable therapeutic targets in mCRC?') and allowing quantitation of gene copy number.

Distribution and prognostic effect of HER2 in CRC
=================================================

Clinical and pathologic features of HER2-positive CRC
-----------------------------------------------------

Tumors originating in the right or left side of the colon and rectum differ in their epidemiology, pathology, mutation profile, and presentation, likely due to distinct embryologic origins of the proximal and distal colon \[[@mdy100-B44]\]. Proximal, or right-sided, tumors are more likely to be hypermethylated or to have microsatellite instability (MSI) than distal tumors \[[@mdy100-B5]\]. Right-sided tumors are also more common in women and the elderly \[[@mdy100-B45]\]. Recent meta-analyses showed a consistent and significant worsening in overall survival (OS) in mCRC tumors originating in the right versus the left side of the colon \[[@mdy100-B46]\].

A number of CRC studies have reported differential expression related to the occurrence of *HER2* amplification based on clinical and pathologic features of the tumor, including primary location (Table [1](#mdy100-T1){ref-type="table"}). Analysis of gene expression and DNA copy number data for patients with CRC in the PETACC-3 adjuvant chemotherapy trial revealed that distal carcinomas (splenic flexure, descending colon, rectum) were more likely to be *HER2* or *EGFR* amplified than proximal carcinomas (cecum, ascending, hepatic flexure, transverse colon) \[[@mdy100-B49]\]. Similar results were reported in advanced CRC, with *HER2* amplifications identified using SISH correlating with a distal location \[[@mdy100-B50]\]. A retrospective analysis identified higher frequencies of HER2 overexpression/amplification in rectal cancers compared with descending colon or right colon cancers \[[@mdy100-B36]\]. A similar trend for more frequent HER2 overexpression in tumors of the sigmoid colon-rectum than the cecum-descending colon was reported in a large series of primary CRC cases \[[@mdy100-B18]\]. In the HERACLES-A trial, among 33 patients with HER2-positive mCRC, 64% had distal tumors and 21% had rectal tumors \[[@mdy100-B37]\]. Retrospective data from the phase II EXPERT-C trial, in patients with high-risk, locally advanced rectal cancer receiving neoadjuvant capecitabine and oxaliplatin plus chemoradiotherapy with or without cetuximab, showed a 4.3% prevalence of HER2 overexpression/amplification using IHC/ISH \[[@mdy100-B51]\]. These findings are in line with the 5.4% HER2-positivity rate for rectal cancers described by Marshall and colleagues \[[@mdy100-B36]\].

In contrast to studies reporting a correlation between *HER2* amplification and tumor location, other researchers have found no such association. In the PETACC-8 FOLFOX-based adjuvant stage III colon cancer study, no significant differences were seen between patient groups on the basis of tumor location \[[@mdy100-B9]\]. A retrospective analysis of two independent cohorts of patients with mCRC observed no significant difference in HER2 expression between right- and left-sided primary tumors \[[@mdy100-B38]\]. A trend toward a decreasing frequency of HER2-positive tumors by IHC was noted from colon to rectum in 3/77 (4%) HER2-positive specimens, but this was not statistically significant (*P *=* *0.251) \[[@mdy100-B23]\]. Several studies have considered the relationship between *KRAS* status and *HER2* amplification in CRC. In a meta-analysis of 3256 patients with mCRC, *HER2* amplification using FISH and gene copy number variation was associated with *KRAS/BRAF* wild-type status at all disease stages: 5.2% wild type versus 1.0% mutated tumors (*P *\<* *0.0001) in stage IV, and 2.1% versus 0.2%, respectively, in stages II--III (*P *=* *0.01) \[[@mdy100-B16]\]. Similarly, in the PETACC-8 study, HER2 alterations determined using NGS, IHC, and FISH were detected in 42 (5.6%) patients with *KRAS* wild-type tumors compared with 22 (2.4%) patients with *RAS* mutation (*P *\<* *0.001) \[[@mdy100-B9]\]. *HER2* amplifications according to SISH were also correlated with *KRAS* wild-type status in 191 patients with mCRC and distant metastases, but only with borderline significance (*P *=* *0.052) \[[@mdy100-B50]\].

In a meta-analysis of 30 studies enrolling 4942 patients with CRC, HER2 expression assessed by IHC was significantly higher in patients with Duke's stage C/D tumors compared with Duke's stage A/B tumors \[odds ratio (OR) 0.335, 95% confidence interval (CI) 0.198--0.568; *P *\<* *0.001\], and in patients with versus without lymph node metastasis (OR 1.987, 95% CI 1.209--3.265; *P *=* *0.007) \[[@mdy100-B52]\]. However, no significant association was found between HER2 expression and CRC location (rectal versus colon; OR 1.123, 95% CI 0.858--1.468; *P *=* *0.399).

Prognostic role of HER2 in CRC
------------------------------

The prognostic role of HER2 in CRC remains uncertain. A negative prognostic impact of HER2 overexpression was proposed in earlier studies \[[@mdy100-B27], [@mdy100-B28]\], but more recent trials have found no association between HER2 amplification and outcome (Table [1](#mdy100-T1){ref-type="table"} \[[@mdy100-B16], [@mdy100-B19], [@mdy100-B21], [@mdy100-B22], [@mdy100-B25]\]). However, in one of the largest study cohorts examined (1645 patients with stages I--IV CRC), a trend toward worse OS was reported for the 26 (1.6%) patients with HER2-positive disease compared with those with HER2-negative disease \[[@mdy100-B18]\]. HER2 was also identified as a poor prognostic indicator in the PETACC-8 study in patients with stage III colon cancer \[[@mdy100-B9]\]. *HER2* alterations were present in 66/1689 evaluated patients (3.9%). *HER2* concordant amplification-positive status by both NGS and FISH, and *HER2* mutation status determined by NGS, were associated with shorter time to recurrence \[hazard ratio (HR) 1.9, 95% CI 1.1--3.2; *P *=* *0.03\] and shorter OS (HR 1.7, 95% CI 0.9--3.2; *P *=* *0.045). This prognostic value was maintained after adjustment for age, treatment, *RAS* mutation, histologic grade, tumor location, pT and pN status, bowel obstruction or perforation, and vascular or lymphatic invasion. Assessment of the potential prognostic effect of *HER2* amplifications in CRC is hindered by the low incidence of these alterations, potentially explaining the inconsistent results of studies addressing this question. Nevertheless, based on available data, it appears that the negative prognostic effect of HER2 is not as marked as that of other alterations such as *BRAF* mutation.

HER2 as a negative biomarker for EGFR-targeted treatments in CRC
================================================================

CRCs are a molecularly heterogeneous group of tumors that often harbor mutations in *KRAS*, *BRAF*, or *PIK3CA*, as well as *HER2* amplifications. These genetic alterations confer resistance to EGFR-targeted therapies in patients with CRC \[[@mdy100-B1], [@mdy100-B53], [@mdy100-B54]\], although currently only selection based on *RAS* status is recommended for excluding patients from anti-EGFR treatment \[[@mdy100-B55]\]. Using data generated from patient-derived mCRC xenografts, Bertotti and coworkers identified *HER2* amplification as a negative predictor of response to cetuximab \[[@mdy100-B1], [@mdy100-B4]\]. Two retrospective clinical series supported that activation of HER2 signaling causes resistance to cetuximab \[[@mdy100-B58], [@mdy100-B59]\]. Yonesaka and colleagues evaluated the clinical impact of *de novo HER2* amplification in 233 cetuximab-treated patients \[[@mdy100-B58]\]. Median progression-free survival (PFS) and OS were almost halved in patients with *HER2-*amplified (*n* = 13) versus nonamplified tumors (*n* = 220): PFS 89 versus 149 days, respectively; OS 307 versus 515 days, respectively; *P *=* *0.0013, log-rank test \[[@mdy100-B58]\]. Survival outcomes were negatively influenced by *HER2* gene copy number in a second series of 170 patients with *KRAS* wild-type mCRC treated with cetuximab or panitumumab alone or in combination with chemotherapy \[[@mdy100-B59]\]. Raghav and coworkers analyzed the impact of *HER2* amplification on the efficacy of anti-EGFR monoclonal antibody therapy in *RAS* and *BRAF* wild-type mCRC \[[@mdy100-B38]\]. They tested *HER2* amplification in a first cohort of 97 patients using IHC and dual ISH (*HER2*: CEP17 ≥ 2.2), and validated their findings in a second cohort of 99 patients, which comprised 37 cases of *HER2* amplification identified by NGS (HER2 gene copy number ≥ 4) and 62 *HER2* nonamplified control patients pretreated with anti-EGFR antibodies. Median PFS on anti-EGFR therapy was significantly shorter in patients with *HER2* amplification versus non-*HER2*-amplification (2.9 months versus 8.1 months, HR 5.0, *P *\<* *0.0001). These findings were confirmed in the validation cohort, in which 69 patients received anti-EGFR treatment after first-line therapy; median PFS was significantly shorter for patients harboring *HER2*-amplified versus nonamplified tumors (2.8 months versus 9.3 months, HR 6.6, *P *\<* *0.0001). Notably, these subgroups had a similar OS (*P *=* *0.86) and PFS while on first-line therapy (*P *=* *0.62) \[[@mdy100-B38]\]. Finally, in the HERACLES-A study, conducted exclusively in HER2-positive mCRC, Sartore-Bianchi and colleagues reported that patients who had previously received panitumumab or cetuximab, evaluable according to rigorous clinical criteria, were resistant to such therapy \[[@mdy100-B6]\].

As summarized in Table [3](#mdy100-T3){ref-type="table"} \[[@mdy100-B4], [@mdy100-B6], [@mdy100-B37], [@mdy100-B38], [@mdy100-B58], [@mdy100-B59]\], the results from these experimental and clinical studies concur that HER2 activation substitutes for EGFR dependence in a fraction of patients with CRC. From a clinical perspective, this notion could potentially impact on optimal therapeutic sequence; however, it should be interpreted with caution since the data are retrospective and need to be validated in prospective clinical studies of patients treated with cetuximab or panitumumab. Table 3.Studies addressing the predictive role of HER2 to EGFR-targeted therapies in mCRCReferencePatients, *NHER2* amplification, % of patientsMethodPrediction of resistance to cetuximab or panitumumabBertotti et al. \[[@mdy100-B4]\]8513.6(*KRAS* WT, cetuximab- or panitumumab-resistant)IHC/FISH (LSI HER2/CEP17 PathVysion probe)*HER2* amplification or overexpression in 6/44 (13.6%) patients with *KRAS* WT tumors without objective response to cetuximab or panitumumab versus 0/45 (0%) patients with objective response (*P*\<0.05)[^a^](#tblfn7){ref-type="table-fn"}Yonesaka et al. \[[@mdy100-B58]\]233 (182 *KRAS* WT)5.6(6.0 *KRAS* WT)FISH (LSI HER2 SO/CEP17 PathVysion probe)Median OS longer in *HER2* nonamplified versus *HER2*-amplified (515 versus 307 days, *P*=0.0013)[^b^](#tblfn8){ref-type="table-fn"}Martin et al. \[[@mdy100-B59]\]162 (*KRAS* WT)20 (*HER2*: CEP17 ≥2 in ≥10% of tumor cells)6 \[*HER2*: CEP17 ≥2 in ≥90% of tumor cells (*HER2*-all-A profile)\]FISH (LSI HER2-neu/CEP17 probe)Median PFS longer in HER2 FISH+ versus HER2 FISH-- (7.4 versus 3.9 months, HR 2.00, 95% CI 1.42--2.83, *P*\<0.0001)[^c^](#tblfn9){ref-type="table-fn"}Sartore-Bianchi et al. \[[@mdy100-B6]\] and Siena et al. \[[@mdy100-B37]\]33 \[[@mdy100-B36]\]100IHC/FISHNo objective response to cetuximab or panitumumab in 15/27 patients \[[@mdy100-B6]\] with HER2-positive tumors assessed for sensitivity to cetuximab or panitumumab according to rigorous criteriaRaghav et al. \[[@mdy100-B38]\]97 (cohort 1);99 (cohort 2)14% cohort 1; *RAS*/*BRAF*-WT cohort 2; not reportedIHC/ISH cohort 1[^d^](#tblfn10){ref-type="table-fn"};NGS cohort 2[^e^](#tblfn11){ref-type="table-fn"}Median PFS on anti-EGFR therapy shorter in patients with HER2-amplified versus HER2 nonamplified tumors (2.9 versus 8.1 months, HR 5.0, *P*\<0.0001) \[cohort 1\];(2.8 versus 9.3 months, HR 6.6, *P*\<0.0001) \[cohort 2\][^9][^10][^11][^12][^13][^14]

HER2 as a novel therapeutic target in CRC
=========================================

HER2 has been investigated as a therapeutic target in mCRC in several small studies during the last decade, but with differing outcomes (Table [4](#mdy100-T4){ref-type="table"} \[[@mdy100-B7], [@mdy100-B37], [@mdy100-B60], [@mdy100-B61]\]). A phase II study assessed the combination of trastuzumab and FOLFOX therapy as second- or third-line treatment of patients with mCRC \[[@mdy100-B61]\]. Notably, patients with IHC HER2 2+ tumors were eligible for enrollment and no ISH testing was planned. Overall, 26 of 653 (4%) of screened tumor blocks scored HER2 ≥ 2+. Among 21 evaluable patients, 5 (24%) achieved a partial response. However, the low rate of HER2 positivity precluded completion of the trial. Results of a subsequent phase II study of first- or second-line trastuzumab plus irinotecan in nine patients with HER2-overexpressing advanced CRC were also reported \[[@mdy100-B60]\]. HER2 overexpression by IHC was evident in 11 of 138 (8.0%) screened tumors (HER2 2+ in 5 patients and HER2 3+ in 6 patients). Partial responses were observed in five of seven evaluable patients (71%), with responses maintained for ≥6 weeks in four patients. The median survival time was 14 months. The study was closed prematurely due to lack of accrual. Table 4.Clinical studies exploiting HER2 as a target for mCRCReferencePhasePatients, *N*HER2 overexpression, %TreatmentLine of treatmentObjective response rate, %*Published studies*Ramanathan et al. \[[@mdy100-B60]\]II9[^a^](#tblfn13){ref-type="table-fn"}3.6 (2+)Trastuzumab and irinotecan1st/2nd714.3 (3+)Clark et al. \[[@mdy100-B61]\]II21[^b^](#tblfn14){ref-type="table-fn"}4.0 (2+/3+)5-FU, leucovorin, oxaliplatin and trastuzumab2nd/3rd24HERACLES-A; Siena et al. \[[@mdy100-B37]\]II3321 (2+)Trastuzumab and lapatinibSalvage30.379 (3+)MyPathway; Hainsworth et al. \[[@mdy100-B8]\]II37100[^c^](#tblfn15){ref-type="table-fn"}Trastuzumab and pertuzumabSalvage38*Ongoing studies*HERACLES-B; Siena et al. \[[@mdy100-B37]\]II30100 (17, 2+; 83, 3+)Pertuzumab and T-DM12nd/3rdNot reportedHERACLES-RESCUE; Siena et al. \[[@mdy100-B37]\]II9100T-DM1SalvageNot reportedS1613 (NCT03365882)IINot availableNot reportedTrastuzumab and pertuzumab or cetuximab and irinotecan2nd or laterNot reportedMODUL (NCT02291289)IINot availableNot reportedCapecitabine, trastuzumab, and pertuzumabBiomarker-driven maintenance therapy after first-line FOLFOX + bevacizumab inductionNot reportedNCT03384940IINot availableNot reportedDS-8201 (investigational trastuzumab conjugated with deruxtecan)3rdNot reported[^15][^16][^17][^18]

A case report was also published of two patients with mCRC and liver metastases who responded to capecitabine, oxaliplatin, and lapatinib while on a clinical trial, but HER2 status was not determined in these patients \[[@mdy100-B62]\].

The inconclusive efficacy findings and poor accruals observed in these studies most likely relate to the absence of a number of important prerequisites in study design, including a mechanistically based HER2-targeted preclinical strategy, patient selection using a validated HER2 scoring system, and a preplanned sample size based on the actual estimated incidence of *HER2* amplification. Moreover, due to concomitant chemotherapy in some studies, it is difficult to establish the specific contribution of HER2 blockade on therapeutic outcome.

Using xenografts derived from patients with mCRC in preclinical therapeutic trials, Bertotti and colleagues identified amplified *HER2* as an effective therapeutic target in cetuximab-resistant CRC \[[@mdy100-B1], [@mdy100-B4]\]. Patient-derived mCRC xenografts with *HER2* amplification were sensitive to HER2-blockade with trastuzumab in combination with lapatinib, but not to either agent alone. These preclinical data formed a strong rationale for clinical trials targeting HER2 genetic alterations in patients with mCRC \[[@mdy100-B1], [@mdy100-B4], [@mdy100-B63]\], paving the way for the HERACLES studies. Recently, results of the HERACLES-A phase II trial of dual HER2-targeted therapy (trastuzumab plus lapatinib) in CRC were presented \[[@mdy100-B6], [@mdy100-B37]\]. This proof-of-concept trial was conducted in patients with *KRAS* wild-type, HER2-positive mCRC who were refractory to standard-of-care treatments, including cetuximab or panitumumab. The HER2 status of the patients was determined using the CRC-specific HERACLES Diagnostic Criteria \[[@mdy100-B17]\]. At the data cutoff of 28 February 2017, 33 patients had been enrolled and were evaluable for response. Complete responses were observed in two patients (6.1%) and partial responses in eight patients (24.2%), giving an overall response rate (ORR) of 30.3% (Table [4](#mdy100-T4){ref-type="table"}) \[[@mdy100-B37]\]. Patients with *HER2* gene copy number ≥9.6 had significantly longer time to progression (median 26.6 weeks versus 13.4 weeks; *P *=* *0.0001) and longer OS (median 53.1 weeks versus 34.0 weeks; *P *=* *0.0058) than those with *HER2* gene copy number \<9.6 \[[@mdy100-B37]\]. The combination regimen was well tolerated in this heavily pretreated population (median of five prior regimens), with no grade 4/5 adverse events and no withdrawals due to patient request \[[@mdy100-B37]\]. Novel methods of generating additional evidence to make this regimen widely available in clinical practice are needed.

Based on preliminary data from the phase II MyPathway trial, investigating agents targeting the HER2, EGFR, BRAF, or Hedgehog pathways in tumors for which these therapies are not currently indicated, the CRC cohort was expanded to enroll 37 patients with HER2-amplified/overexpressed mCRC who had exhausted standard treatments \[[@mdy100-B8]\]. Patients received a combination of trastuzumab and pertuzumab. The ORR was 38% (95% CI 22.2--56.4) (Table [4](#mdy100-T4){ref-type="table"}). Four (11%) patients had stable disease for \>4 months \[[@mdy100-B8]\]. Median PFS was 4.6 months (95% CI 1.6--9.8) and median OS was 10.3 months (95% CI 7.2--22.1) \[[@mdy100-B7]\]. ORR was higher in patients with wild-type versus mutated *KRAS* (52.0% versus 0%, respectively), and in patients with left-sided colon cancer (42.9%) or rectal cancer (45.5%) versus right-sided colon cancer (12.5%) \[[@mdy100-B7]\].

In support of the available preclinical and clinical data, anecdotal case reports of patients with HER2-positive mCRC who have achieved substantial clinical benefit with targeted anti-HER2 therapy have recently been published \[[@mdy100-B64]\].

Challenges and open issues toward clinical application
======================================================

Are HER2 mutations actionable therapeutic targets in mCRC?
----------------------------------------------------------

A number of *HER2* activating mutations, sometimes in concomitance with *HER2* amplification, have been identified in CRC. These mutations are present in approximately 7% of CRCs, based on TCGA data, and may co-exist with *HER2* gene amplification in around 20% of cases \[[@mdy100-B63]\]. They are similar to those seen in breast cancer and include kinase domain single nucleotide variations such as V842I, V777L, and L755S, and extracellular domain mutations such as S310F \[[@mdy100-B1], [@mdy100-B5], [@mdy100-B63]\]. Introduction of these four mutations into immortalized mouse colon epithelial cells triggered HER2 signaling pathways, with increases in HER2, MAPK, and AKT phosphorylation noted relative to *HER2* wild-type transduced cells \[[@mdy100-B63]\]. These *HER2* mutations also dramatically increased the number of colonies formed in soft agar, demonstrating enhanced anchorage-independent growth. Furthermore, these *HER2*-activating mutations produced resistance to the EGFR monoclonal antibodies, cetuximab or panitumumab, when transfected into two cetuximab-sensitive CRC cell lines \[[@mdy100-B63]\]. In patient-derived CRC xenografts containing the *HER2*-activating mutations S310Y or L866M, treatment with trastuzumab, neratinib, or lapatinib alone delayed tumor growth, but after 30 days, the mice developed large tumors. However, dual HER2-targeted therapy with trastuzumab plus either neratinib or lapatinib produced durable tumor regression, similar to that observed in *HER2*-amplified mCRC \[[@mdy100-B63]\]. Lack of effect of neratinib monotherapy in *HER2*-mutant CRC was recently confirmed in a basket trial of 125 patients with different tumors harboring *HER2* mutations, including 12 patients with CRC \[[@mdy100-B67]\]. In the latter cohort, there were no objective responses and median PFS was just 1.8 months. In the MyPathway trial, eight patients with mCRC had tumors that harbored *HER2* mutations and one of these (12.5%) achieved an investigator-assessed objective response with the combination of pertuzumab and trastuzumab (H. Hurwitz, personal communication). Overall, these data indicate that monotherapy with HER2 small molecule inhibitors is ineffective. It remains to be determined whether HER2-directed combination therapy with monoclonal antibodies or monoclonal antibodies plus small molecule inhibitors can be effective in *HER2*-mutated tumors.

What are the determinants of resistance to HER2-directed therapies?
-------------------------------------------------------------------

Understanding the mechanisms of primary and secondary resistance to HER2 blockade is a priority to develop more effective and additional lines of therapy, because 40%--50% of patients treated within the HERACLES-A and MyPathway trials did not achieve partial response or prolonged stable disease despite *HER2* amplification \[[@mdy100-B6], [@mdy100-B8]\]. Moreover, even in patients displaying disease control, secondary resistance occurs in almost all cases. Preclinical models of HER2 therapeutic blockade were carried out in quadruple negative mCRC (i.e. *KRAS*, *NRAS*, *PIK3CA*, and *BRAF* wild-type) since aberrations in one or more of these effectors could impact on and compensate for the inhibition exerted by HER2-directed therapy \[[@mdy100-B4], [@mdy100-B6], [@mdy100-B7]\]. Based on these findings, the HERACLES-A trial was performed in *KRAS* exon 2 wild-type patients, thus positive clinical results can be applied to this subset of patients only. Anecdotally, we treated two patients harboring *KRAS* exon 2 mutations off-study, and neither obtained a partial response (S. Siena and A. Sartore-Bianchi, personal communication). The MyPathway study included patients with *KRAS*-mutated CRC, but none of these patients responded to HER2-directed therapy \[[@mdy100-B7]\], confirming the biologic rationale underlying resistance.

Extensive studies utilizing pre- and post-treatment tissue samples are ongoing to define the molecular basis of primary and secondary resistance to trastuzumab and lapatinib in HER2-positive mCRC. Preliminary data obtained by molecular profiling of plasma samples collected during the HERACLES-A trial suggest that alterations affecting HER2 parallel pathways controlled by receptor tyrosine kinases, and/or downstream effectors such as RAS and PI3KA, are implicated in primary and secondary resistance to HER2 blockade (G. Siravegna, unpublished data). Once completed, these analyses may have important implications for the selection of patients with mCRC most likely to benefit from anti-HER2 therapies, as well as providing the basis for designing new treatments in patients who experience disease progression.

When to test for HER2 and how an HER2-directed therapy may integrate in the treatment algorithm of mCRC
-------------------------------------------------------------------------------------------------------

Based on the consistent therapeutic actionability of dual HER2 inhibition in refractory mCRC \[[@mdy100-B6], [@mdy100-B8]\], it is feasible that a similar effect may be obtained by targeting HER2 in earlier lines of treatment and testing for *HER2* alongside other biomarkers being assessed at the time of diagnosis of metastatic disease \[[@mdy100-B68]\]. *HER2* amplification in mCRC can be considered an orphan molecular entity. Difficulties in developing a targeted treatment of this cancer, up to the level of regulatory approval, are being addressed with tools developed in the context of international initiatives \[[@mdy100-B69]\]. While speculative in the absence of randomized data, hypotheses can be made regarding clinical trials with HER2-directed therapies aimed at defining optimal positioning and combination partners in the treatment algorithm of mCRC (Figure [1](#mdy100-F1){ref-type="fig"}). National and international collaborations and translational studies designed to understand mechanisms of resistance to HER2 inhibition will be of paramount importance to the successful development of these trials. Based on available results \[[@mdy100-B6], [@mdy100-B8]\], these studies should be restricted to *KRAS* exon 2 wild-type tumors. Although data regarding the potential impact on sensitivity exerted by other *RAS* mutations outside *KRAS* exon 2 are lacking, application of expanded *RAS* wild-type criteria might be more realistic. Finally, since *HER2* amplification might act as a negative predictor of response to EGFR-targeted treatments, HER2-directed therapy before cetuximab or panitumumab in the continuum of care of these patients should be considered a reasonable option.

![Scenarios for positioning of clinical trials with HER2-targeted treatments in mCRC.](mdy100f1){#mdy100-F1}

Available data suggest a ≥30% ORR with dual HER2 inhibition, which compares favorably with results of second-line standard treatment options in patients with *RAS* wild-type CRC previously treated with a first-line regimen including an anti-EGFR component. In patients who do not receive an anti-EGFR in first-line, second-line chemotherapy plus anti-EGFR (especially in *RAS* and *BRAF* selected cases \[[@mdy100-B70]\]) might produce good responses, but given the potential negative predictive role of *HER2* amplification, this is unlikely to be the case in this patient population. In light of these considerations, and of the expected lower toxicity of a chemotherapy-free regimen, a dual HER2-targeted combination might be an optimal choice for a trial in this setting, either after FOLFOX/FOLFIRI with an anti-EGFR or a vascular endothelial growth factor (VEGF)-targeted component, and compared with standard second-line options.

A hypothetical alternative might be starting with an HER2-targeted component during first-line treatment. However, it is uncertain whether a chemotherapy-free HER2-targeted regimen would perform better than standard FOLFOX/FOLFIRI or FOLFOXIRI+/-- EGFR- or VEGF-targeted options, which produce ORRs of 59%--65% in this setting \[[@mdy100-B71], [@mdy100-B72]\]. Therefore, a combination of HER2-directed treatment with chemotherapy should be considered, taking into account safety issues for the combination and the fact that HER2 might act as a negative predictive biomarker of response to EGFR-targeted treatment. For the latter reason, comparison between a FOLFOX/FOLFIRI backbone with an HER2-directed agent versus the same chemotherapy with an anti-EGFR agent might offer a straight-forward answer on the optimal sequencing in *RAS* wild-type tumors, and whether or not to offer an anti-EGFR drug upfront to these patients.

Conclusion
==========

*HER2* amplification is a clinically relevant genetic alteration in mCRC as documented by the HERACLES \[[@mdy100-B6], [@mdy100-B37]\] and MyPathway \[[@mdy100-B7], [@mdy100-B8]\] studies. This biomarker can be screened for with established diagnostic tools \[[@mdy100-B16], [@mdy100-B17]\], occurs in a sizable 5% of patients with *KRAS* wild-type mCRC, and can potentially act as a predictor of lack of benefit to anti-EGFR monoclonal antibodies \[[@mdy100-B4]\].

HER2-targeted therapy compares favorably with emerging therapeutic strategies for mCRC such as BRAF-directed therapy and immunotherapy with checkpoint inhibitors. *HER2* amplification displays an incidence similar to that of MSI-high (MSI-H) tumors (5%) \[[@mdy100-B73]\] and lower than that of *BRAF* mutations (10%); however, compared with BRAF-directed combinations (ORR 16%--21%; median PFS 4.2 months \[[@mdy100-B74]\]), responses achieved so far in clinical studies with HER2-directed therapies are higher (ORR 30%--38% \[[@mdy100-B6], [@mdy100-B8]\]) and more durable (median PFS 5.2 months \[[@mdy100-B6]\]), resembling results obtained with checkpoint inhibitors in MSI-H tumors \[[@mdy100-B75]\]. The toxicity of HER2-targeted combinations is also less than BRAF- or MSI-H-directed therapeutics \[[@mdy100-B74], [@mdy100-B75]\]. Thus, HER2-directed therapies appear to reconcile the merits of precision medicine (rapid and deep induction of tumor shrinkage) with those of immunotherapy (durable responses and better tolerability).

Although evidence from phase III trials with HER2-targeted agents is lacking, randomized studies will take a long time to achieve results in such a selected population \[[@mdy100-B69]\]. The strong underlying biologic rationale \[[@mdy100-B4]\], consistent actionability at the therapeutic level \[[@mdy100-B6], [@mdy100-B8]\], and favorable comparison with other precision medicine approaches support consideration for conditional approval of HER2-targeted agents for clinical use by regulatory agencies.
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======================
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[^1]: S. Siena and A. Sartore-Bianchi authors contributed equally as senior authors.

[^2]: Present address: Global Product Development Medical Affairs, F. Hoffmann-La Roche Ltd., Basel, Switzerland.

[^3]: For FISH and NGS, RFS and OS analyses performed by pooling *HER2* amplifications and mutations.

[^4]: CGS, comprehensive genomic sequencing; CISH, chromogenic in situ hybridization; CRC, colorectal cancer; EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization; *HER2*, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization; NGS, next-generation sequencing; OS, overall survival; PFS, progression-free survival; RFS, recurrence-free survival.

[^5]: At least five consecutive cells.

[^6]: If additional scoring does not allow a definitive result to be rendered, multiple options are feasible: (1) consultation between scorer and pathologist regarding selection of malignant cells or tumor areas for scoring, (2) use of an alternative chromosome 17 probe in a retest to calculate the ratio, (3) selecting a different tumor block, (4) using genomics or an alternative analytic method to evaluate *HER2* amplification.

[^7]: Circumferential, basolateral, or lateral.

[^8]: CEP, chromosome enumeration probe.

[^9]: Data supported by a molecularly annotated platform of patient-derived xenografts.

[^10]: Acquired *HER2* amplification in two cases of secondary resistance to cetuximab.

[^11]: HER2 FISH+: *HER2* gene copy number gain (presence of ≥4 copies of the *HER2* gene in ≥40% of cells) and *HER2*-amplified (*HER2* gene amplification defined as *HER2*: CEP17 ≥2 in ≥10% of cells).

[^12]: *HER2* amplification defined as *HER2*: CEP17 ≥ 2.2.

[^13]: *HER2* amplification defined as *HER2* ≥ 4 copies.

[^14]: HR, hazard ratio; mCRC, metastatic colorectal cancer; WT, wild type.

[^15]: The study was prematurely closed due to low accrual.

[^16]: The low rate of HER2 positivity precluded completion of the trial.

[^17]: Patients with HER2 mutations were also eligible; see text for details.

[^18]: DS-8201, trastuzumab deruxtecan; 5-FU, 5-fluorouracil; T-DM1, trastuzumab emtansine.
